Raymond James on Aardvark (AARD): 'we think ARD-101’s value proposition as potentially best-in-class
Tweet Send to a Friend
Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $47.00 price target on Aardvark Therapeutics Inc (NASDAQ: AARD)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
